Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 125

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 125
---
NLS’s and Kadimastem’s ability to scale in a cost -effectivemanner; •developments and projections relating to NLS’s and Kadimastem’s competitors and industry; •NLS’s and Kadimastem’s expectations regarding its ability to obtain and maintain intellectual property protection and not infringe on the rights of others; •expectations regarding the time during which NLS will be an EGC under the JOBS Act; •NLS’s and Kadimastem’s future capital requirements and sources and uses of cash; •NLS’s and Kadimastem’s ability to obtain funding for their operations; •NLS’s and Kadimastem’s business, expansion plans and opportunities; •NLS’s and Kadimastem’s management and board of directors; •the listing of NLS’s securities on Nasdaq; •geopolitical risk and changes in applicable laws or regulations; •fluctuations in exchange rates between the foreign currencies in which NLS and Kadimastem typically do business and the United States dollar; and •the outcome of any known and unknown litigation and regulatory proceedings. These forward -lookingstatements are based on information available as of the date of this proxy statement/prospectus, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward -lookingstatements should not be relied upon as representing the views of NLS or Kadimastem 23 as of any subsequent date, and neither NLS nor Kadimastem undertake any obligation to update forward -lookingstatements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. You should not place undue reliance on these forward -lookingstatements in deciding how to grant your proxy or to instruct how your vote should be cast or how you should vote your shares on the proposals set forth in this proxy statement/prospectus. As a result of a number of known and unknown risks and uncertainties, the actual results or performance of NLS may be materially different from those expressed or implied by these forward -lookingstatements. Some factors that could cause actual results to differ include: •the occurrence of any event, change or other circumstances that could delay the Merger or give rise to the termination of the Merger Agreement; •the outcome of any legal proceedings that may be instituted against NLS or Kadimastem following announcement of the proposed Merger and transactions contemplated